Karo Bio: Full-year Report 2002 -- Quarterly Report, October-December 2002
07. Februar 2003 02:52 ET
|
Karo Bio
HUDDINGE, Sweden, Feb. 7, 2003 (PRIMEZONE) -- Karo Bio (Other OTC:KARBF) (Stockholm:KARO):
-- A clinical development candidate was selected in July in the project
with Merck & Co., Inc. for...
Karo Bio Reorganizes R&D Operations
28. Januar 2003 06:41 ET
|
Karo Bio
HUDDINGE, Sweden, Jan. 28, 2003 (PRIMEZONE) -- Karo Bio (Other OTC:KARBF) has promoted Dr. Anders Berkenstam, Director R&D Sweden, to Vice President R&D Sweden and Dr. Paul Hamilton, Director...
Karo Bio: Quarterly Report, July-September 2002
16. Oktober 2002 04:48 ET
|
Karo Bio
HUDDINGE, Sweden, Oct. 16, 2002 (PRIMEZONE) -- Karo Bio (Other OTC:KARBF):
-- Significant preclinical milestone reached in the collaboration
with Merck & Co., Inc. Milestone payment...
Karo Bio and Bristol-Myers Squibb Extend Obesity Collaboration
09. Oktober 2002 02:46 ET
|
Karo Bio
HUDDINGE, Sweden, Oct. 9, 2002 (PRIMEZONE) -- Karo Bio (Other OTC:KARBF) (Stockholm:KARO) and Bristol-Myers Squibb Company (NYSE:BMY) have been collaborating for development of a new obesity...
Milestone Reached in the Karo Bio - Merck & CO., Inc. Collaboration
17. Juli 2002 05:49 ET
|
Karo Bio
HUDDINGE, Sweden, July 17, 2002 (PRIMEZONE) -- A significant preclinical milestone has been achieved in the estrogen receptor collaboration between Merck & Co., Inc and Karo Bio. The event is...
Karo Bio Quarterly Report, April-June 2002
16. Juli 2002 02:45 ET
|
Karo Bio
HUDDINGE, Sweden, July 16, 2002 (PRIMEZONE) -- Karo Bio:
The partner projects continue to make progress in compound characterization for selection of clinical development candidates.
The internal...
Karo Bio's Capital Markets Day in London
16. Mai 2002 02:40 ET
|
Karo Bio
HUDDINGE, Sweden, May 16, 2002 (PRIMEZONE) -- Karo Bio, a leading international drug discovery company focusing on nuclear receptors as drug targets, will today present an overview of the Company for...
Karo Bio's Annual General Meeting
26. April 2002 03:21 ET
|
Karo Bio
HUDDINGE, Sweden, April 26, 2002 (PRIMEZONE) -- Karo Bio:
At Karo Bio AB's Annual General Meeting on April 25, 2002 the following was resolved.
Dividend
No dividend is to be paid for the...
Today's Annual General Meeting in Karo Bio AB
25. April 2002 04:56 ET
|
Karo Bio
HUDDINGE, Sweden, April 25, 2002 (PRIMEZONE) -- The Board of Directors of Karo Bio AB has decided to withdraw its proposal to the Annual General Meeting to introduce a Stock Option Program. Before...
Karo Bio: Quarterly Report, January-March 2002 (with link)
24. April 2002 03:12 ET
|
Karo Bio
HUDDINGE, Sweden, April 24, 2002 (PRIMEZONE) -- Karo Bio:
-- Clinical development for the first obesity compound discontinued.
The project continues and a program to replace the compound is...